Skip to content
Sign in
In depthStableHealthFirst published 2026-11-13 12:00

China approves its first oral GLP-1 obesity treatment: Lilly’s Foundayo

The approval brings a once-daily pill into a market where GLP-1 medicines for weight management had previously been approved only as injections. The decision comes as forecasts point to a larger population with overweight or obesity and rising sales of weight-management therapies.

Orforglipron 3D
Jovan.gec
Once daily

Foundayo is taken once a day and is intended for chronic weight management in obese or overweight adults.1

1.2%

Lilly shares rose 1.2% in US pre-market trading after the announcement.2

11% over 72 weeks

The weight-loss result cited for Foundayo was 11% over 72 weeks.2

Story

What China’s approval of Foundayo changes

1 12 1 12

1 1 1 1

2 12 2 2

2 2 2 2

2 2 12 12

2 2 2 2

2 2 2 12

2 2 2 2

2 12 2 2

History

How it came to this
  1. Before the approvalChinese GLP-1 weight-management approvals were injectableThe reported regulatory landscape had no approved oral GLP-1 weight-management treatment before Foundayo.
  2. August (year not specified)Novo’s oral Wegovy application was acceptedNovo said its application to sell an oral version of Wegovy in China had been accepted.
  3. Thursday (date not specified)China announced Foundayo’s approvalThe National Medical Products Administration announced approval of orforglipron, the country’s first oral GLP-1 obesity treatment.
  4. NowFirst Orforglipron becomes China’s first approved oral GLP-1 obesity treatment

Impact

Spreading outward, level by level
  1. Level 1Treatment form

    The approval adds a pill to the GLP-1 weight-management options approved in China, where the previously approved medicines were injectable.12

    Fact
  2. Level 2Lilly’s commercial plans

    Lilly said it was working toward a commercial launch in China and would supply Foundayo to authorised healthcare institutions; it did not comment on price.2

    Fact
  3. Level 3Competition

    Foundayo is expected to compete with Lilly’s weekly injection and injectable products from Novo, Pfizer and Innovent Biologics. Novo has also reported acceptance of its application for an oral Wegovy, but the facts do not say that product is approved in China.2

    Fact
  4. Level 4Potential market context

    The approval may add to competition in a market where an analyst forecasts substantial growth in annual Chinese GLP-1 weight-management sales; that forecast covers the market, not Foundayo alone.

    Analysis

Sources

What each source supports
1
South China Morning Post world
2026-11-13 01:01
Original ↗
Supports 4 points
Citing: National Medical Products Administration
2
freemalaysiatoday.com
2026-11-12 17:30
Original ↗
Supports 11 points
Citing: Chinese regulators, Lilly, Novo, Pfizer, Innovent Biologics, Eli Lilly, Danish drugmaker, China’s National Health Commission, Yang Huang, JP Morgan, JD.com

Written by AI from the sources listed below: every fact was checked word for word against its source, and inference is marked apart. How we write

2026-11-13 03:26 First published